Zealand Pharma ASZLDPF 62 Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus rates ZLDPF with a GF Score™ of 62/100 and a GF Value™ of $2,410.77 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 377 Biotechnology companies, Zealand Pharma AS ranks better than 55.17% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Zealand Pharma AS's
Operating Income
for the
three
months ended in Mar. 2026 was $-83 Mil. Zealand Pharma AS's Interest Expense for the
three
months ended in Mar. 2026 was $-1 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Zealand Pharma AS has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Zealand Pharma AS's Interest Coverage or its related term are showing as below:
ZLDPF'
s Interest Coverage Range Over the Past 10 Years
Min: 244.8 Med: 244.8 Max: 264.37
Current: 264.37
ZLDPF's Interest Coverage is ranked better than 55.17% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs ZLDPF: 264.37
Zealand Pharma AS (OTCPK:ZLDPF) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Zealand Pharma AS Interest Coverage Related Terms
Zealand Pharma AS Interest Coverage Historical Data
* Premium members only.
The historical data trend for Zealand Pharma AS's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ZLDPF vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Zealand Pharma AS's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Zealand Pharma AS did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Zealand Pharma AS (ZLDPF) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Zealand Pharma AS and its competitors. Over the past decade, Zealand Pharma AS's Interest Coverage has ranged from 244.80 to 264.37. According to the industry distribution chart, Zealand Pharma AS ranks #169 out of 377 companies in the Biotechnology industry, placing it in the top 44.8%.
Is Zealand Pharma AS's Interest Coverage too high?
Zealand Pharma AS's current Interest Coverage is 0 (At Loss). Over the past 10 years, this metric has ranged from a low of 244.80 to a high of 264.37. Based on the distribution chart, Zealand Pharma AS ranks #169 out of 377 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zealand Pharma AS has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #169 out of 377 companies for Interest Coverage. This puts Zealand Pharma AS in the upper half of its industry. The industry median Interest Coverage is 106.07. Historically, Zealand Pharma AS's own Interest Coverage has ranged from 244.80 to 264.37 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Zealand Pharma AS and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zealand Pharma AS's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPF) is currently considered Possible Value Trap. The stock's GF Value™ is $2,410.77, compared to a current price of $42.89 — trading 98.2% below its estimated fair value. The current Interest Coverage is 0 (At Loss). Zealand Pharma AS's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zealand Pharma AS (ZLDPF) Overvalued in 2026?
Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued.
The current stock price of $42.89 is trading 98.2% below its estimated GF Value™ of $2,410.77.
GuruFocus considers Zealand Pharma AS to be Possible Value Trap.
Key valuation signals for ZLDPF:
Interest Coverage: 0 (At Loss)
GF Value™: $2,410.77 vs. price of $42.89 (98.2% below fair value)
No single metric tells the full story. See the ZLDPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
62GF Score
Get the complete analysis for ZLDPF
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLDPF has been successfully added to your 
